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Introduction {#sec001}
============

Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver that ranks second in cancer deaths in developing countries, sixth in cancer deaths in developed countries \[[@pone.0206853.ref001]\], and third in the incidence of malignant tumors in China \[[@pone.0206853.ref002]\]. The onset of HCC is occult, and early symptoms and signs are not easy to detect. Most patients are diagnosed with advanced-stage disease; therefore, treatment is not effective. According to recent epidemiological data, the 5-year survival rate of patients with HCC is only 18% \[[@pone.0206853.ref001]\]. To improve the prevention and treatment of HCC, it is necessary to clarify its pathogenesis.

The formation of HCC is a multistep process of multiple pathogenies. The causes include chronic hepatitis virus infection, *Aspergillus flavus* toxin damage, long-term drinking, and extensive smoking. However, not everyone exposed to these factors develops HCC. Increasing evidence suggests that HCC is triggered not only by external factors but also by genetic factors.

The base excision repair pathway repairs damaged DNA, thereby maintaining genomic integrity. However, this pathway is prone to errors, resulting in DNA damage and cancer \[[@pone.0206853.ref003]\]. XRCC1 is a key molecule in the DNA repair process, with a key role in the integrity and stability of the genome and in the pathogenesis and carcinogenesis of various types of tumors. It has been reported that *XRCC1* gene polymorphisms are associated with lung, esophageal, breast, bladder, and gastrointestinal cancer \[[@pone.0206853.ref003]--[@pone.0206853.ref007]\]. Additionally, a clinical study has shown that *XRCC1* 280 is significantly associated with the number of tumors, tumor size, and tumor location and is an independent risk factor for poor prognosis in patients with HCC \[[@pone.0206853.ref008]\]. Similarly, *XRCC1* 399 is significantly associated with clinical prognosis. After transcatheter arterial chemoembolization, the risk of death in patients with the A/A+G/A genotype is lower and the median survival time is longer (11.2 months) than those in patients with other genotypes \[[@pone.0206853.ref009]\].

Many studies have explored the relationship between gene polymorphisms and HCC susceptibility, but a unified conclusion is lacking. In this study, a meta-analysis of studies of XRCC1 Arg194Trp, Arg280His, and Arg399Gln was used to determine the relationship between these polymorphisms and susceptibility to HCC.

Materials and methods {#sec002}
=====================

Literature search {#sec003}
-----------------

A comprehensive search was performed against various databases, i.e., PubMed, Web of Science, Cochrane Library, the Chinese National Knowledge Infrastructure, and the Wanfang standard database, to identify case--control studies published through March 1, 2018 that examined the association between *XRCC1* polymorphisms and HCC risk. Searches were performed using various combinations of customized terms and the MeSH-indexed terms "X-ray repair cross complementation group 1" OR "XRCC1" AND "variation" OR "variability" AND "hepatocellular carcinoma" OR "liver cancer", without restrictions on publication language. The following sequential search strategy was applied for each database: (\#1) 'DNA repair pathway': ab, ti OR 'repair gene'/exp 'OR 'repair reaction'/exp OR 'repair response'/exp OR 'Base Excision Repair/BER'/exp; (\#2) 'X-ray repair cross-complementation group 1': ab, ti OR 'XRCC1': ab, ti OR' X-ray repair complementing defective repair in Chinese hamster cells 1'/exp; (\#3) 'variation': ab, ti OR 'polymorphism': ab, ti OR 'SNP': ab, ti OR 'Single Nucleotide Polymorphism'/exp OR 'genetic polymorphism'/exp OR 'genetic variability'/exp; (\#4) 'liver cancer': ab, ti OR 'hepatocellular carcinoma': ab, ti OR 'primary hepatic carcinoma'/exp OR 'primary liver cancer'/exp; (\#5) \#1 AND \#2 AND \#3 AND \#4.

Study inclusion and exclusion criteria {#sec004}
--------------------------------------

### Inclusion criteria {#sec005}

The inclusion criteria were as follows: (1) studies that examined the association between XRCC1 Arg194Trp, Arg280His, and Arg399Gln and susceptibility to HCC in the Chinese population; (2) studies of humans; (3) case--control studies; (4) studies reporting genotype distributions in the case group and the control group.

### Exclusion criteria {#sec006}

The exclusion criteria were as follows: (1) simple case reports, reviews, or commentaries; (2) subjects were single HCC families, animals, or other organisms; (3) the association between XRCC1 Arg194Trp, Arg280His, and Arg399Gln and susceptibility to HCC was not evaluated; (4) data were incomplete; (5) repeated publication (only the most recent or most complete studies were included). The process of literature screening is shown in [Fig 1](#pone.0206853.g001){ref-type="fig"}.

![Flow diagram of study selection for the meta-analysis.\
CNKI, Chinese National Knowledge Infrastructure Database. WFSD, the Wanfang standard database.](pone.0206853.g001){#pone.0206853.g001}

The following data were carefully extracted and examined by two assessors: author, publication year, country, case/control number, source, method, Hardy--Weinberg equilibrium (HWE) test, and quality score. The basic features of these studies are shown in [Table 1](#pone.0206853.t001){ref-type="table"}.

10.1371/journal.pone.0206853.t001

###### The general data of the observation group and the control group were included in the meta-analysis.

![](pone.0206853.t001){#pone.0206853.t001g}

  Variable                                 Years   Country    Cases/Controls   Case   Control   Source   Method   HWE   Score                              
  ---------------------------------------- ------- ---------- ---------------- ------ --------- -------- -------- ----- ---------- ----- ---------- ------ ----
  Arg194Trp                                                                                                                                                
  Su \[[@pone.0206853.ref010]\]            2008    China      100/111          46     50        4        57       43    11         PB    PCR-RFLP   0.50   10
  Kiran \[[@pone.0206853.ref011]\]         2009    India      63/143           8      43        12       27       64    52         PB    PCR-RFLP   0.36   7
  Zeng \[[@pone.0206853.ref012]\]          2010    China      500/507          280    183       37       270      199   38         HB    Taqman     0.87   11
  Bo \[[@pone.0206853.ref013]\]            2011    China      130/130          94     31        5        116      12    2          PB    PCR-RFLP   0.02   9
  Tang \[[@pone.0206853.ref014]\]          2011    China      150/150          94     41        15       81       58    11         PB    PCR-RFLP   0.89   10
  Bo \[[@pone.0206853.ref015]\]            2012a   China      60/60            41     13        6        53       5     2          PB    PCR-RFLP   0.00   8
  Han \[[@pone.0206853.ref016]\]           2012    China      150/158          72     47        31       84       46    28         PB    PCR-RFLP   0.00   8
  Yuan \[[@pone.0206853.ref017]\]          2012a   China      252/250          119    115       18       128      101   21         HB    PCR-RFLP   0.86   9
  Zeng \[[@pone.0206853.ref018]\]          2012    China      46/46            23     23        26       20       HB    PCR-RFLP   ---                     
  Wu \[[@pone.0206853.ref019]\]            2014    China      218/277          151    55        12       198      68    11         PB    PCR-RFLP   0.10   10
  Yang \[[@pone.0206853.ref020]\]          2015    China      118/120          55     53        10       58       45    17         HB    PCR-RFLP   0.10   5
  Krupa \[[@pone.0206853.ref021]\]         2017    Polish     65/50            57     5         3        41       8     1          HB    Taqman     0.43   5
  Guo \[[@pone.0206853.ref022]\]           2012    China      410/410          264    109       37       292      96    23         HB    PCR-RFLP   0.00   11
  Arg280His                                                                                                                                                
  Su \[[@pone.0206853.ref010]\]            2008    China      100/111          79     20        1        87       21    3          PB    Taqman     0.23   10
  Wu \[[@pone.0206853.ref023]\]            2009    China      100/60           77     22        1        47       13    0          PB    PCR-RFLP   0.34   7
  Kiran \[[@pone.0206853.ref011]\]         2009    India      63/155           19     30        14       91       29    35         PB    PCR-RFLP   0.00   6
  Zeng \[[@pone.0206853.ref012]\]          2010    China      500/507          414    79        7        417      87    3          HB    Taqman     0.50   11
  Tang \[[@pone.0206853.ref014]\]          2011    China      150/150          138    11        1        123      26    1          PB    PCR-RFLP   0.77   10
  Han \[[@pone.0206853.ref016]\]           2012    China      150/158          81     35        34       82       36    40         PB    PCR-RFLP   0.00   8
  Yuan \[[@pone.0206853.ref017]\]          2012a   China      252/250          193    53        6        206      39    5          HB    PCR-RFLP   0.06   9
  Yuan \[[@pone.0206853.ref024]\]          2012b   China      350/400          272    73        5        329      64    7          HB    PCR-RFLP   0.07   10
  Bo \[[@pone.0206853.ref015]\]            2012a   China      60/60            42     12        6        51       6     3          PB    PCR-RFLP   0.00   8
  Bo \[[@pone.0206853.ref025]\]            2012b   China      90/90            64     18        8        78       9     3          PB    PCR-RFLP   0.00   8
  Zeng \[[@pone.0206853.ref018]\]          2012    China      46/46            39     7         35       11       HB    PCR-RFLP   ---                     
  Gulnaz \[[@pone.0206853.ref026]\]        2013    Pakistan   50/74            24     17        9        44       27    3          HB    PCR-RFLP   0.65   6
  He \[[@pone.0206853.ref027]\]            2015    China      77/40            61     16        0        36       4     0          PB    PCR-RFLP   0.74   7
  Krupa \[[@pone.0206853.ref021]\]         2017    Polish     65/50            57     7         1        36       11    3          HB    Taqman     0.12   5
  Arg399Gln                                                                                                                                                
  Yao \[[@pone.0206853.ref028]\]           2014    China      1486/1996        777    608       101      1437     520   39         PB    PCR-RFLP   0.31   13
  Yu \[[@pone.0206853.ref029]\]            2003    China      577/389          301    223       53       218      143   28         PB    PCR-RFLP   0.50   11
  Yang \[[@pone.0206853.ref030]\]          2004    China      69/136           34     7         28       58       15    63         HB    PCR-RFLP   0.00   7
  Long \[[@pone.0206853.ref031]\]          2004    China      140/536          72     63        5        362      159   15         HB    PCR-RFLP   0.62   10
  Kirk \[[@pone.0206853.ref032]\]          2005    Gambia     149/294          120    26        3        248      43    3          HB    PCR-RFLP   0.46   11
  Borentain \[[@pone.0206853.ref033]\]     2007    France     56/89            27     21        8        27       43    19         PB    Taqman     0.81   8
  Ren \[[@pone.0206853.ref034]\]           2008    China      50/92            32     14        4        46       41    5          PB    PCR-RFLP   0.28   7
  Su \[[@pone.0206853.ref010]\]            2008    China      100/111          40     53        7        69       31    11         PB    Taqman     0.01   9
  Kiran \[[@pone.0206853.ref011]\]         2009    India      63/142           25     33        5        45       70    27         PB    PCR-RFLP   0.98   7
  Jia \[[@pone.0206853.ref035]\]           2010    China      136/136          53     66        17       78       45    13         HB    PCR-RFLP   0.10   10
  Zeng \[[@pone.0206853.ref012]\]          2010    China      500/507          286    180       34       304      167   36         HB    Taqman     0.05   11
  Pan \[[@pone.0206853.ref036]\]           2011    China      202/236          45     105       52       68       112   56         PB    PCR-RFLP   0.46   9
  Tang \[[@pone.0206853.ref014]\]          2011    China      150/150          41     94        15       84       54    12         PB    PCR-RFLP   0.43   10
  Guo \[[@pone.0206853.ref022]\]           2012    China      410/410          203    136       71       227      128   55         PB    PCR-RFLP   0.00   11
  He \[[@pone.0206853.ref037]\]            2012    China      113/113          80     23        10       97       12    4          PB    PCR-RFLP   0.00   10
  Han \[[@pone.0206853.ref016]\]           2012    China      150/158          32     78        40       46       73    39         PB    PCR-RFLP   0.35   9
  Bo \[[@pone.0206853.ref015]\]            2012a   China      60/60            38     14        8        52       5     3          PB    PCR-RFLP   0.00   8
  Zeng \[[@pone.0206853.ref018]\]          2012    China      46/46            33     13        25       21       HB    PCR-RFLP   ---                     
  Mohana \[[@pone.0206853.ref038]\]        2013    India      93/93            36     45        12       32       51    10         HB    PCR-RFLP   0.12   5
  Bose \[[@pone.0206853.ref039]\]          2013    India      55/209           22     29        4        75       88    46         HB    PCR-RFLP   0.04   8
  Gulnaz \[[@pone.0206853.ref024]\]        2013    Pakistan   50/74            19     14        17       27       32    15         HB    PCR-RFLP   0.34   6
  Wu \[[@pone.0206853.ref019]\]            2014    China      218/277          108    74        36       161      87    29         PB    PCR-RFLP   0.00   9
  He \[[@pone.0206853.ref027]\]            2015    China      77/40            47     26        4        27       12    1          PB    PCR-RFLP   0.80   7
  Krupa \[[@pone.0206853.ref021]\]         2017    Polish     65/50            42     15        8        32       12    6          HB    Taqman     0.02   4
  Santonocito \[[@pone.0206853.ref040]\]   2017    Italia     89/99            37     45        7        59       38    2          HB    PCR        0.14   5
  Bazgir \[[@pone.0206853.ref041]\]        2017    Irania     50/101           12     18        20       31       56    14         HB    PCR-RFLP   0.16   10

Notes: PB, population-based; HB, hospital-based; HWE, Hardy-Weinberg equilibrium; c1:Arg; c2: For Arg194Trp, Trp; ForArg280His, His; ForArg399Gln, Gln.

Quality assessment {#sec007}
------------------

The Newcastle--Ottawa Scale (NOS) was used to evaluate the quality of all eligible studies. The NOS provides a quality rating, ranging from 0 to 10, based on criteria covering three study aspects: study group selection, comparability of cases and controls, and exposure of cases and controls. Results of the quality assessment are shown in [Table 2](#pone.0206853.t002){ref-type="table"}. We also used the quality assessment criteria ([S1 Table](#pone.0206853.s004){ref-type="supplementary-material"}), derived from a previously published meta-analysis of non-Hodgkin lymphoma \[[@pone.0206853.ref042]\], for further assessment. Quality scores of studies ranged from 0 to 15. Studies with scores ≤ 9 were considered of low quality, while those with scores \> 9 were considered of high quality.

10.1371/journal.pone.0206853.t002

###### Results of quality assessment using the Newcastle-Ottawa Scale for cohort studies.
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  Study (au, year)   A1   A2   A3   A4   B     C1   C2   C3   Score
  ------------------ ---- ---- ---- ---- ----- ---- ---- ---- -------
  Su 2008            ★    ★    ★    ★    ★     ★    ★    ★    8
  Kiran 2009         ★    ★    ★    ★    ★     ★    ★    一   7
  Zeng 2010          ★    ★    一   ★    ★     ★    ★    ★    7
  Bo 2011            ★    ★    ★    ★    ★     ★    ★    一   7
  Tang 2011          ★    ★    ★    ★    ★     ★    ★    一   7
  Bo 2012a           ★    ★    ★    ★    ★     ★    ★    一   7
  Han 2012           ★    ★    ★    ★    ★ ★   ★    ★    ★    9
  Yuan 2012a         ★    ★    一   ★    ★     ★    ★    ★    7
  Zeng 2012          ★    ★    一   ★    ★     ★    ★    一   6
  Yao 2014           ★    ★    ★    ★    ★ ★   ★    ★    一   8
  Wu 2014            ★    ★    ★    ★    ★     ★    ★    一   7
  Yang 2015          ★    ★    一   ★    ★     ★    ★    一   6
  Krupa 2017         ★    ★    一   ★    ★     ★    ★    一   6
  Wu 2009            ★    ★    ★    ★    ★     ★    ★    一   7
  Yuan 2012b         ★    ★    一   ★    ★     ★    ★    ★    7
  Gnlnaz 2013        ★    ★    一   ★    ★     ★    ★    一   6
  He 2015            ★    ★    ★    ★    ★     ★    ★    ★    8
  Yu 2003            ★    ★    ★    ★    ★     ★    ★    一   7
  Yang 2004          ★    ★    一   ★    ★ ★   ★    ★    一   7
  Long 2004          ★    ★    一   ★    ★     ★    ★    一   6
  Bo 2012b           ★    ★    ★    ★    ★     ★    ★    一   7
  Kirk 2005          ★    ★    一   ★    ★ ★   ★    ★    一   7
  Borentain 2007     ★    ★    ★    ★    ★     ★    ★    一   7
  Ren 2008           ★    ★    ★    ★    ★     ★    ★    一   7
  Jia 2010           ★    ★    一   ★    ★     ★    ★    一   6
  Pan 2011           ★    ★    ★    ★    ★ ★   ★    ★    一   8
  Guo 2012           ★    ★    ★    ★    ★ ★   ★    ★    一   8
  He 2012            ★    ★    ★    ★    ★     ★    ★    一   7
  Mohana 2013        ★    ★    一   ★    ★     ★    ★    一   6
  Bose 2013          ★    ★    一   ★    ★ ★   ★    ★    一   7
  Santonocito 2017   ★    ★    一   ★    ★ ★   ★    ★    一   7
  Bazgir 2017        ★    ★    ★    ★    ★     ★    ★    ★    8

Notes: A1, Representativeness of the exposed cohort; A2, Selection of the non-exposed cohort; A3, Ascertainment of exposure; A4, Demonstration that outcome of interest was not present at start of study; B, Comparability of cohorts on the basis of the design or analysis; C1, Assessment of outcome; C2, Was follow-up long enough for outcomes to occur; C3, Adequacy of follow up of cohorts; A, B, C represent Selection, Comparability, Outcome, respectively;★and★★indicate compliance with the requirements of the definition, for which specific meaning see [S1 Text](#pone.0206853.s003){ref-type="supplementary-material"}.

Data analysis {#sec008}
-------------

RevMan 5.3 was used for meta-analysis, and Q and I^2^ values were used to evaluate heterogeneity. If the heterogeneity test showed P \> 0.1 or I^2^ \< 50%, a fixed effect model was used, and heterogeneity was considered relatively low; if P \< 0.1 or I^2^ \> 50%, heterogeneity was considered high, and a subgroup analysis or sensitivity analysis was used to study the source of heterogeneity. The odds ratio (OR) and 95% confidence interval (CI) were used as indicators of the effect for each result. HWE was calculated using HWSIM (<http://krunch.med.yale.edu/hwsim/website>). P \> 0.05 indicated equilibrium; P \< 0.05 indicated a departure from HWE. A sensitivity analysis was used to evaluate the stability of the results. False-positive report probabilities (FPRP) were calculated using the FPRP calculation spreadsheet (see <http://jncicancerspectrum.oupjournals.org/jnci-/content/vol96/issue6>) to assess positive results. The FPRP threshold was set to 0.2, and the prior probability was set to 0.1 to detect the OR. A significant result with an FPRP value of less than 0.2 indicated a notable finding. All statistical tests were two-sided, and P \< 0.05 was considered statistically significant. Trial sequential analysis (TSA) was used to reduce random errors and increase the robustness of the conclusions, using a 5% significance level for type I errors and a 20% significance level for type II errors, and the amount of information and a TSA monitoring boundary were determined.

Results {#sec009}
=======

Study selection and characteristics {#sec010}
-----------------------------------

The meta-analysis was conducted according to the recommendations of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement ([S1 Checklist](#pone.0206853.s001){ref-type="supplementary-material"}) and "Meta-analysis on Genetic Association Studies" statement ([S2 Checklist](#pone.0206853.s002){ref-type="supplementary-material"}). Systemic literature searches identified 32 articles \[[@pone.0206853.ref010]--[@pone.0206853.ref041]\], eight of which discussed all three loci, four of which discussed two loci, and twenty of which discussed a single locus. Of the 32 studies, 13 analyzed the XRCC1 Arg194Trp polymorphism, 14 analyzed Arg280His, and 26 analyzed Arg399Gln.

The XRCC1 Arg194Trp, Arg280His, and Arg399Gln polymorphisms were evaluated by calculating ORs and 95% CIs under homozygous, heterozygous, dominant, and recessive models. The results are summarized in [Table 3](#pone.0206853.t003){ref-type="table"}.

10.1371/journal.pone.0206853.t003

###### Overall and subgroup analysis of the XRCC1 polymorphisms and cancer risk.
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  Varible         N    Homozygous genetic model   Heterozygous genetic model   Dominant genetic model         Recessive genetic model                                                                           
  --------------- ---- -------------------------- ---------------------------- ------------------------------ ------------------------------ ------ ---- ----------------- ------ ---- ----------------- ------ ----
  Arg194Trp            Trp/Trp vs Arg/Arg         Trp/Trp vs Arg/Trp           Trp/Trp + Arg/Trp vs Arg/Arg   Trp/Trp vs Arg/Arg + Arg/Trp                                                                      
  All             13   1.13(0.90,1.41)            0.34                         10                             1.42(1.24,1.62)                0.01   57   1.14(1.01,1.29)   0.01   53   1.02(0.82,1.26)   0.05   44
  All-China       11   1.14(0.91,1.44)            0.25                         21                             1.41(1.23,1.61)                0.03   52   1.15(1.01,1.30)   0.01   58   1.11(0.89,1.39)   0.20   27
  All-HWE         8    0.92(0.69,1.21)            0.78                         0                              1.39(1.18,1.64)                0.01   60   1.00(0.87,1.16)   0.52   0    0.82(0.63,1.06)   0.15   35
  All-HWE-China   6    0.91(0.68,1.23)            0.64                         0                              1.38(1.16,1.62)                0.06   53   0.99(0.85,1.15)   0.44   0    0.91(0.68,1.21)   0.33   13
  All-PB          7    1.18(0.84,1.67)            0.37                         8                              1.72(1.37,2.14)                0.01   68   1.26(1.03,1.54)   0.01   68   0.97(0.71,1.33)   0.04   55
  All-HB          6    1.09(0.82,1.47)            0.23                         29                             1.26(1.07,1.50)                0.50   0    1.08(0.94,1.26)   0.37   14   1.06(0.79,1.40)   0.20   34
  Arg280His            His/His vs Arg/Arg         His/His vs Arg/His           His/His + Arg/His vs Arg/Arg   His/His vs Arg/Arg + Arg/His                                                                      
  All             13   1.43(0.91,2.25)            0.15                         31                             1.20(1.02,1.41)                0.00   69   1.19(1.02,1.38)   0.00   67   1.15(0.84,1.56)   0.22   23
  All-China       10   1.14(0.77,1.69)            0.47                         0                              1.14(0.96,1.35)                0.03   53   1.13(0.96,1.33)   0.01   56   1.10(0.76,1.59)   0.51   0
  All-HWE         9    1.28(0.61,2.67)            0.18                         33                             1.05(0.88,1.26)                0.03   53   1.08(0.91,1.28)   0.02   57   1.31(0.77,2.23)   0.17   34
  All-HWE-China   7    1.15(0.59,2.22)            0.68                         0                              1.08(0.90,1.31)                0.03   56   1.10(0.91,1.32)   0.05   52   1.09(0.58,2.05)   0.59   0
  All-PB          7    1.37(0.80,2.35)            0.24                         26                             1.34(1.03,1.73)                0.00   77   1.30(1.03,1.64)   0.00   75   1.03(0.71,1.48)   0.45   0
  All-HB          6    1.47(0.62,3.47)            0.11                         46                             1.12(0.91,1.37)                0.11   47   1.12(0.92,1.36)   0.06   53   1.49(0.84,2.63)   0.12   45
  Arg399Gln            Gln/Gln vs Arg/Arg         Gln/Gln vs Arg/Gln           Gln/Gln + Arg/Gln vs Arg/Arg   Gln/Gln vs Arg/Arg + Arg/Gln                                                                      
  All             25   1.61(1.40,1.85)            0.00                         69                             1.55(1.42,1.68)                0.00   74   1.56(1.45,1.69)   0.00   79   1.40(1.23,1.59)   0.00   64
  All-China       17   1.78(1.53,2.08)            0.00                         67                             1.66(1.52,1.82)                0.00   77   1.68(1.54,1.82)   0.00   81   1.47(1.27,1.70)   0.00   60
  All-HWE         17   1.80(1.51,2.13)            0.00                         72                             1.58(1.44,1.73)                0.00   79   1.64(1.50,1.79)   0.00   82   1.53(1.30,1.79)   0.00   67
  All-HWE-China   10   2.00(1.65,2.42)            0.00                         73                             1.71(1.55,1.89)                0.00   82   1.77(1.61,1.95)   0.00   84   1.57(1.31,1.87)   0.00   69
  All-PB          14   1.83(1.55,2.17)            0.00                         74                             1.66(1.51,1.83)                0.00   81   1.73(1.57,1.90)   0.00   84   1.51(1.29,1.77)   0.00   69
  All-HB          11   1.19(0.93,1.53)            0.00                         74                             1.29(1.10,1.50)                0.04   47   1.24(1.07,1.43)   0.00   57   1.17(0.92,1.48)   0.01   58

Quantitative synthesis {#sec011}
----------------------

The XRCC1 Arg399Gln polymorphism was related to the risk of HCC in the Arg399Gln homozygous genetic model (OR = 1.61, 95% CI: 1.40--1.85, P~heterogeneity~ \< 0.05; [Fig 2](#pone.0206853.g002){ref-type="fig"}), recessive genetic model (OR = 1.40, 95% CI: 1.23--1.59, P~heterogeneity~ \< 0.05; [Fig 3](#pone.0206853.g003){ref-type="fig"}), dominant genetic model (OR = 1.56, 95% CI: 1.45--1.69, P~heterogeneity~ \< 0.05; [Fig 4](#pone.0206853.g004){ref-type="fig"}), and heterozygous genetic model (OR = 1.55, 95% CI: 1.42--1.68, P~heterogeneity~ \< 0.05). Arg399Gln was also associated with susceptibility to HCC in the Chinese population based on the homozygous genetic model (OR = 1.78, 95% CI: 1.53--2.08, P~heterogeneity~ \< 0.05) and recessive genetic model (OR = 1.47, 95% CI: 1.27--1.70, P~heterogeneity~ \< 0.05), suggesting that Gln/Gln is a risk factor for HCC. Limiting the analysis to studies demonstrating HWE, inconsistent results were obtained ([Table 3](#pone.0206853.t003){ref-type="table"}). In the Indian population, the Arg399Gln homozygous genetic model (OR = 0.49, 95% CI: 0.27--0.87, P~heterogeneity~ = 0.15) and recessive genetic model (OR = 0.51, 95% CI: 0.30--0.87, P~heterogeneity~ = 0.07) indicated that Gln/Gln is a protective factor for liver cancer. Similarly, the funnel plot for Arg399Gln was asymmetric, implying a slight publication bias ([Fig 5](#pone.0206853.g005){ref-type="fig"}, funnel plot for the Arg399Gln homozygous model; [Fig 6](#pone.0206853.g006){ref-type="fig"}, funnel plot for the Arg399Gln recessive model; [Fig 7](#pone.0206853.g007){ref-type="fig"}, funnel plot for the Arg399Gln dominant model).
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The XRCC1 Arg280His polymorphism was not associated with the risk of HCC under the Arg280His homozygous genetic model (OR = 1.43, 95% CI: 0.91--2.25, P~heterogeneity~ = 0.15), recessive genetic model (OR = 1.15, 95% CI: 0.84--1.56, P~heterogeneity~ = 0.22), dominant genetic model (OR = 1.19, 95% CI: 1.02--1.38, P~heterogeneity~ \< 0.01), or heterozygous genetic model (OR = 1.20, 95% CI: 1.02--1.41, P~heterogeneity~ \< 0.01). In addition, no association was observed for any subgroups.

Similarly, the XRCC1 Arg194Trp was not related to susceptibility to HCC under the Arg194Trp homozygous genetic model (OR = 1.13, 95% CI: 0.90--1.41, P~heterogeneity~ = 0.34), recessive genetic model (OR = 1.02, 95% CI: 0.82--1.26, P~heterogeneity~ = 0.05), dominant genetic model (OR = 1.14, 95% CI: 1.01--1.29, P~heterogeneity~ \< 0.05), or heterozygous genetic model (OR = 1.42, 95% CI: 1.24--1.62, P~heterogeneity~ \< 0.05). No significant association was found in any of the subgroups.

Sensitivity analysis {#sec012}
--------------------

Owing to the slight heterogeneity of the results for Arg194Trp, a sensitivity analysis was performed, which indicated that Tang et al. \[[@pone.0206853.ref014]\] was the source of the heterogeneity. After eliminating this study, Arg194Trp was unrelated to susceptibility to HCC based on the homozygous genetic model (OR = 1.13, 95% CI: 0.78--1.64, P~heterogeneity~ = 0.55), heterozygous genetic model (OR = 1.17, 95% CI: 0.97--1.39, P~heterogeneity~ \< 0.01), dominant genetic model (OR = 1.14, 95% CI: 0.96--1.35, P~heterogeneity~ \< 0.01), and recessive genetic model (OR = 0.96, 95% CI: 0.67--1.36, P = 0.79).

The full analysis suggested that Arg280His was not associated with susceptibility to HCC under the homozygous genetic model (OR = 1.56, 95% CI: 1.11--2.18, P~heterogeneity~ = 0.19) or recessive genetic model (OR = 1.45, 95% CI: 1.05--1.99, P~heterogeneity~ = 0.07). However, many studies had small sample sizes. After those with N \< 200 were eliminated, the Arg280His homozygous genetic model (OR = 1.13, 95% CI: 0.78--1.64, P~heterogeneity~ = 0.55), heterozygous genetic model (OR = 1.17, 95% CI: 0.97--1.39, P~heterogeneity~ \< 0.01), dominant genetic model (OR = 1.14, 95% CI: 0.96--1.35, P~heterogeneity~ \< 0.01), and recessive genetic model (OR = 0.96, 95% CI: 0.67--1.36, P~heterogeneity~ = 0.79), still indicated a lack of evidence for an association with susceptibility to HCC.

TSA, combined genotype analysis, and FPRP analysis {#sec013}
--------------------------------------------------

We performed a TSA to reduce random errors and increase the robustness of the conclusions. The TSA of the Arg194Trp polymorphism model showed that the cumulative z-curve did not cross the traditional cut-off value, nor did it cross the TSA threshold. Moreover, the expected amount of information was not obtained, indicating that the difference in the XRCC1 Arg194Trp polymorphism between the HCC group and the control group was not statistically significant and that additional experiments are needed ([Fig 8](#pone.0206853.g008){ref-type="fig"}). The TSA of the allele models for the Arg280His polymorphism showed that the cumulative z-curve crossed the traditional cut-off value but did not cross the TSA threshold, and the cumulative amount of information was insufficient ([Fig 9](#pone.0206853.g009){ref-type="fig"}). The TSA of the allele models for the Arg399Gln polymorphism showed that the cumulative z-curve crossed both the traditional threshold and the TSA threshold, and the accumulated information was sufficient, indicating that no further evidence was needed to verify the conclusion ([Fig 10](#pone.0206853.g010){ref-type="fig"}).
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HWE-based studies were performed using the combined genotype analysis. XRCC1 Arg194Trp + Arg280His was not associated with HCC susceptibility under the homozygous genetic model (OR = 1.00, 95% CI: 0.78--1.29) or recessive genetic model (OR = 0.90, 95% CI: 0.71--1.14). When Arg399Gln was combined with either or both of the other polymorphisms, correlations with HCC susceptibility were detected, indicating that the main SNP related to HCC risk is XRCC1 Arg399Gln ([Table 4](#pone.0206853.t004){ref-type="table"}).

10.1371/journal.pone.0206853.t004

###### Combined genotype analysis for three XRCC1 single nucleotide polymorphisms.
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  All-HWE                             Homozygous genetic model   Heterozygous genetic model   Dominant genetic model   Recessive genetic model
  ----------------------------------- -------------------------- ---------------------------- ------------------------ -------------------------
  Arg194Trp + Arg280His               0.96(0.73,1.26)            1.22(1.08,1.38)              1.03(0.93,1.15)          0.90(0.71, 1.14)
  Arg194Trp + Arg399Gln               1.50(1.29,1.74)            1.53(1.41,1.66)              1.42(1.32,1.53)          1.29(1.12,1.48)
  Arg280His + Arg399Gln               1.77(1.49,2.10)            1.45(1.33,1.57)              1.50(1.39,1.62)          1.51(1.29,1.76)
  Arg194Trp + Arg280His + Arg399Gln   1.49(1.29,1.73)            1.43(1.33,1.54)              1.36(1.27,1.46)          1.29(1.13,1.47)

[Table 5](#pone.0206853.t005){ref-type="table"} shows the FPRP values for our positive results using different prior probability levels. Assuming a prior probability of 0.1 and a specific genotype with an OR of 1.5, the statistical power was 0.856, and the FPRP value was \< 0.001 for the recessive model of the XRCC1 Arg399Gln polymorphism. Thus, the risk of liver cancer was elevated for all individuals. In addition, the FPRP values for the Chinese population, the all-HWE-compliant population, the China-HWE-compliant subgroup, and the population-based (PB) group were all less than 0.2, indicating reliable results.

10.1371/journal.pone.0206853.t005

###### False-positive report probability values for associations between the risk of hepatocellular carcinoma and the frequency of genotypes of XRCC1 gene.
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  Arg399Gln Homozygous   Crude OR(95%CI)   Statistical power   P-value   Prior probability                                       
  ---------------------- ----------------- ------------------- --------- ------------------- ----------- ----------- ----------- -----------
  All                    1.61(1.40,1.85)   0.159               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.000**
  All-China              1.78(1.53,2.08)   0.016               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.000**
  All-HWE                1.80(1.51,2.13)   0.174               0.000     **0.041**           **0.114**   0.585       0.934       0.993
  All-HWE-China          2.00(1.65,2.42)   0.002               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.000**
  All-PB                 1.83(1.55,2.17)   0.011               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.000**
  Arg399Gln Recessive                                                                                                            
  All                    1.40(1.23,1.59)   0.856               0.000     **0.000**           **0.000**   **0.004**   **0.003**   0.025
  All-China              1.47(1.27,1.70)   0.607               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.003**
  All-HWE                1.53(1.30,1.79)   0.402               0.000     **0.000**           **0.000**   **0.000**   **0.000**   **0.003**
  All-HWE-China          1.57(1.31,1.87)   0.305               0.000     **0.000**           **0.000**   **0.000**   **0.001**   **0.014**
  All-PB                 1.51(1.29,1.77)   0.467               0.000     **0.000**           **0.000**   **0.000**   **0.001**   **0.008**

Discussion {#sec014}
==========

HCC is a serious digestive system tumor that is typically detected at an advanced stage, when treatment approaches are limited and prognosis is poor. Studies have shown that bad eating habits, alcohol consumption, environment, work stress, and emotional changes are risk factors for HCC in high-incidence areas. However, not all individuals exposed to these risk factors develop HCC, indicating that genetic susceptibility may be important. Defects or inadequate DNA repair caused by polymorphisms in DNA repair genes increase the risk of cancer. Previous studies have reported that *XRCC1* expression is elevated in colorectal \[[@pone.0206853.ref043]\], esophageal \[[@pone.0206853.ref044]\], and lung cancer tissues \[[@pone.0206853.ref045]\]. Similarly, Krupa et al. \[[@pone.0206853.ref021]\] showed that the mRNA expression of *XRCC1* in HCC tissues was significantly lower than that in adjacent non-lesional tissues. The expression of *XRCC1* in cancer tissues is closely related to the intrinsic genetic phenotype. Thus, DNA repair gene polymorphisms may play an important role in susceptibility to liver cancer.

Many studies have shown that the XRCC1 Arg399Gln polymorphism is associated with HCC risk, while susceptibility is lower for carriers of Arg194Trp and Arg280His; however, the results of previous studies have been inconsistent. Guo et al. \[[@pone.0206853.ref022]\] found that, compared with Arg/Arg, XRCC1 194Trp/Trp was significantly associated with risk of HCC, and individuals carrying XRCC1 399Gln/Gln showed an increased risk of HCC. However, Yang et al. \[[@pone.0206853.ref030]\], found that this polymorphism was not related to HCC risk. Su et al. \[[@pone.0206853.ref010]\] suggested that the Arg194Trp and Arg280His polymorphisms are not related to susceptibility to HCC but that the Arg399Gln polymorphism is a susceptibility factor for HCC, with Gln/Gln as a risk factor, consistent with the results of this study. Jia et al. \[[@pone.0206853.ref035]\] found that the XRCC1 399 Arg/Gln genotype conferred increased HCC risk. Han et al. \[[@pone.0206853.ref016]\] found that the median survival rate of individuals carrying the XRCC1 Gln/Gln genotype was significantly lower than that of individuals carrying the XRCC1 Arg/Arg genotype. However, Zeng et al. \[[@pone.0206853.ref012]\] suggested that XRCC1 Arg194Trp, Arg280His, and Arg399Gln are not predisposing factors for HCC but found that there was an additive interaction between *XRCC1* polymorphisms and smoking, drinking, and chronic hepatitis B virus (HBV) infection. Similarly, Yuan et al. \[[@pone.0206853.ref017]\] found that XRCC1 Arg194Trp and Arg280His are not associated with the risk of HCC but that Arg399Gln is associated with a significantly increased risk of HCC in the background of HBV infection and family history.

In a previous meta-analysis, Xu et al. \[[@pone.0206853.ref046]\] found that Arg280His was associated with the risk of HCC and that His/His increases the risk of disease. Li et al. \[[@pone.0206853.ref047]\] found that Arg194Trp and Arg280His were not related to the risk of HCC, but that 399 Arg/Gln was significantly associated with the risk of HCC, and the results were still significant in studies demonstrating HWE. Similarly, Liu et al. \[[@pone.0206853.ref048]\] indicated that there was a significant correlation between Arg399Gln and susceptibility to HCC in the Chinese population. Shi et al. \[[@pone.0206853.ref049]\] found that 399 Arg/Gln was unrelated to HCC but that it was significantly correlated with the incidence of HCC in southern China, suggesting that there was genetic heterogeneity. In our comprehensive meta-analysis of Arg194Trp, Arg280His, and Arg399Gln case--control studies, we grouped the populations that satisfied HWE, calculated FPRPs, and performed a TSA to increase the robustness of the conclusions. Our findings showed that the Arg399Gln polymorphism increased susceptibility to liver cancer, while Arg194Trp and Arg280His were not associated with susceptibility to liver cancer. However, additional samples are needed to further evaluate these findings.

Zhu et al. \[[@pone.0206853.ref050]\] studied the relationship between the *XPC* genotype and DNA repair ability in an alkaline comet assay challenged by benzo\[a\]pyrene diol epoxide (BPDE) and γ radiation. Healthy subjects with the XPC Lys939Gln variant allele (AC and CC) were found to have significantly increased rates of DNA damage induced by BPDE and γ irradiation compared to homozygous wild-type (AA) subjects. In contrast, subjects with the Ala499Val variant allele (CT and TT) showed reduced BPDE- and γ radiation-induced DNA damage. Reinardy et al. \[[@pone.0206853.ref051]\] evaluated echinoderms after 24 h of exposure to genotoxic agents (UV-C, hydrogen peroxide, and bleomycin) and found that adult sea urchin coelomocytes and larvae with *XRCC1* polymorphisms showed more mutations in the body cavity after recovery, indicating the heterogeneous response of echinoderms to DNA damage and revealing that DNA repair ability within host cells may be regulated by specific gene polymorphisms. Therefore, XRCC1 plays a crucial role in maintaining genomic stability and preventing cancer. We hypothesize that people exposed to risk factors for liver cancer are more likely to develop *XRCC1* mutations, resulting in an altered DNA repair capacity and increased susceptibility to liver cancer. In addition, Kuptsova et al. \[[@pone.0206853.ref052]\] found that after a standard chemotherapy induction regimen in elderly patients with acute myeloid leukemia, different DNA repair gene variants repaired chemotherapy-induced DNA damage, which may affect drug toxicity and treatment response to varying degrees. Xuan et al. \[[@pone.0206853.ref053]\] found that XRCC1 can increase the base repair ability and promote tumor resistance via the tumor drug resistance pathway, suggesting that variants in the DNA repair pathway may impact patient outcomes and treatment-related responses. Wang et al. \[[@pone.0206853.ref054]\] found that XRCC1 protein levels are significantly down-regulated in gastric cancer lesions compared with levels in adjacent non-cancerous tissues in a study of the prognosis and predictive role of XRCC1 in patients treated with surgery alone or in combination with adjuvant chemotherapy. Low expression of XRCC1 was significantly associated with shorter overall survival and clinicopathological features of unassisted patients. The prognosis of patients treated with adjuvant fluorouracil-leucovorin-oxaliplatin was significantly improved compared with that for surgery alone. However, this effect was only significant in the low expression group; therefore, XRCC1 protein expression in tumors is a novel candidate prognostic marker and response predictor. Li et al. \[[@pone.0206853.ref055]\] performed a prognostic analysis of 150 patients with HCC and found that patients carrying the Gln/Gln genotype showed a significantly lower median survival than individuals with the Arg/Arg genotype. Compared with Arg/Arg carriers, the median survival rate of Arg/Gln + Gln/Gln carriers was reduced. Therefore, we hypothesize that the XRCC1 Gln/Gln genotype can be used as a negative indicator in liver cancer and that XRCC1 can serve as a potential indicator for clinical diagnosis and prognosis, as well as a new potential target for clinical treatment in HCC cases.

Our study had some limitations. We observed high heterogeneity among studies, which may be related to the choice of the control population, differences in living environments, and differences in family genetic background. Second, many studies included in the analysis had small sample sizes. To ensure the stability of the results, we evaluated the FPRP and performed a TSA. In addition, we detected a slight publication bias, suggesting that additional well-designed studies are needed. Our results showed that the XRCC1 Arg399Gln Gln/Gln genotype is a risk factor for liver cancer in the Chinese population.

Conclusions {#sec015}
===========

*XRCC1* polymorphisms are still a major topic in cancer research. Previous meta-analyses of these polymorphisms have yielded inconsistent results. In this study, relevant literature was obtained to resolve this controversy. Our results indicated that XRCC1 Arg399Gln is significantly associated with the risk of HCC, especially in the Chinese population. In addition, there was a slight publication bias, suggesting the need for further research.
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